Treatment and prevention of ascitic fluid infection (Q44284068)

1 December 2017

1 reference

title

Treatment and prevention of ascitic fluid infection (English)

1 reference

1 December 2017

Carine Chagneau

1

1 reference

1 December 2017

language of work or name

French

0 references

publication date

1 April 2004

1 reference

Gastroenterologie Clinique et Biologique

1 December 2017

published in

1 reference

1 December 2017

volume

28 Spec No 2

1 reference

1 December 2017

page(s)

B138-45

1 reference

Spontaneous bacterial peritonitis: an update

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis.

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Spontaneous bacterial peritonitis: an explosion of information

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Epidemiology of Severe Hospital‐Acquired Infections in Patients with Liver Cirrhosis: Effect of Long‐Term Administration of Norfloxacin

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Aztreonam vs. cefotaxime in the treatment of gram-negative spontaneous peritonitis in cirrhotic patients.

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Use of ceftriaxone in the treatment of bacterial infections in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Five days of ceftriaxone to treat spontaneous bacterial peritonitis in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: a prospective study of twenty-seven cases in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopenia

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin.

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Selective intestinal decontamination prevents spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Antibiotic Prophylaxis for the Prevention of Bacterial Infections in Cirrhotic Patients with Ascites: A Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

The Effect of Ciprofloxacin in the Prevention of Bacterial Infection in Patients With Cirrhosis After Upper Gastrointestinal Bleeding

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(04)95249-9

7 January 2021

10.1016/S0399-8320(04)95249-9

Identifiers

DOI

1 reference

1 December 2017

1 reference